Are the benefits of value-based insurance design conclusive?

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Questions about the clinical significance of improvements to medication adherence resulting from value-based insurance design (VBID) policies persist in the literature. Given the lack of conclusive evidence about effectiveness, in addition to concerns about the cost of implementing VBID programs, it is perhaps not surprising that VBID is not more widely used by managed care plans. Although VBID holds promise for improving chronic medication use, additional evidence is needed if VBID is to become universally adopted. DISCLOSURES: No funding contributed to the writing of this article. The author currently receives funding from Blue-Cross Blue-Shield of Minnesota for unrelated research.

Original languageEnglish (US)
Pages (from-to)736-738
Number of pages3
JournalJournal of Managed Care and Specialty Pharmacy
Volume25
Issue number7
DOIs
StatePublished - Jul 1 2019
Externally publishedYes

Bibliographical note

Funding Information:
No funding contributed to the writing of this article. The author currently receives funding from Blue-Cross Blue-Shield of Minnesota for unrelated research.

Publisher Copyright:
Copyright © 2019, Academy of Managed Care Pharmacy. All rights reserved.

Keywords

  • Humans
  • Managed Care Programs/economics
  • Medication Adherence/statistics & numerical data
  • Value-Based Health Insurance/economics

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'Are the benefits of value-based insurance design conclusive?'. Together they form a unique fingerprint.

Cite this